Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Compared to other common HIV treatments, dolutegravir-based regimens maintained viral suppression even without perfect adherence.
The small single-site study will need to be replicated in a larger group of adolescents.
Many participants on two-drug regimens had more treatment under their belt and more chronic conditions.
However, all integrase inhibitors were associated with similar weight gain.
People whose viral load rebounds on Tivicay may not need to switch medications.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
This is especially the case for people globally who don’t have access to such newer regimens.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.